picankibart vs risankizumab

NCT05645627 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 500 participants. The sponsor reports that picankibart met its co-primary endpoints, with 80.3% of picankibart patients reaching PASI90 (at least 90% skin clearance) at week 16, compared with 2.0% of placebo patients, a highly significant difference.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT02684370 · Phase 3 · completed

This randomized, triple-blind, placebo- and active-controlled trial used validated skin-clearance measures as its primary endpoints, and risankizumab achieved a highly statistically significant improvement over placebo on both: 75.3% vs 4.9% achieving PASI90, and 87.8% vs 7.8% achieving clear-or-almost-clear skin at Week 16.

NCT05377580 · Phase 2 · completed

This trial randomized 150 patients with moderate-to-severe ulcerative colitis to picankibart at several doses or placebo under double-blind conditions, with clinical remission at Week 12 as the primary measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT03398148 · Phase 2/3 · completed

Design meets the 'strong' test: randomized, double-blind (participant and investigator masked), placebo-controlled, large adequately powered sample (n=1555 treated), hard clinical/endoscopic composite endpoint (Adapted Mayo Score remission including endoscopic subscore), and the primary comparison was statistically significant in the favorable direction for all randomized dose arms in both substudies.